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Abstract
Introduction: Apathy adversely affects prognosis and survival of patients with fron-
totemporal dementia (FTD). We test whether apathy develops in presymptomatic
genetic FTD, and is associated with cognitive decline and brain atrophy.
Methods: Presymptomatic carriers of MAPT, GRN or C9orf72 mutations (N = 304),
and relatives without mutations (N= 296) underwent clinical assessments andMRI at
baseline, and annually for 2 years. Longitudinal changes in apathy, cognition, gray mat-
ter volumes, and their relationships were analyzed with latent growth curvemodeling.
Results: Apathy severity increased over time in presymptomatic carriers, but not in
non-carriers. In presymptomatic carriers, baseline apathy predicted cognitive decline
over two years, but not vice versa. Apathy progression was associated with baseline
low graymatter volume in frontal and cingulate regions.
Discussion: Apathy is an early marker of FTD-related changes and predicts a subse-
quent subclinical deterioration of cognition before dementia onset. Apathy may be a
modifiable factor in those at risk of FTD.
KEYWORDS
apathy, cognitive decline, genetic frontotemporal dementia, longitudinal design, MRI, presymp-
tomatic carriers
1 INTRODUCTION
Apathy is a common and disabling feature of frontotemporal demen-
tia (FTD). It is part of the diagnostic criteria for behavioral variant of
FTD (bvFTD),1 and frequently occurs across all FTDvariants.2,3 Apathy
is a multifaceted construct that describes dysfunctional goal-directed
behavior, arising from affective, behavioral, and cognitive impairments.
FTD has been associated with concurrent affective, behavioral, and
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cognitive apathy symptoms,4 which worsen the prognosis in terms
of survival,5 disability6–9 and functional independence. Better under-
standing of the causes and consequences of apathy and its role in
the clinical progression of FTD is vital to develop effective treatment
strategies, including preventive strategies in the context of genetic risk
of FTD.
Previous imaging studies have identified structural correlates and
changes associated with apathy in FTD. The severity of apathy corre-
lates with widespread atrophy in frontotemporal areas, including the
dorsolateral, ventromedial and orbital prefrontal cortex, anterior cin-
gulate cortex, and insula and basal ganglia3,10–12 (see13,14). In peo-
ple with symptomatic FTD, apathy is associated with the severity of
executive function impairment,12,15 including deficits in workingmem-
ory, decision making, selective/sustained attention, planning, process-
ing speed, inhibitory processes and mental/cognitive flexibility.12,15–18
Deficits in executive function occur in both behavioral and aphasic
syndromes of FTD, with subtler impairments in the presymptomatic
phase.19–21 Indeed, executive dysfunction, like apathy, is a diagnos-
tic criterion for bvFTD1 and shares several anatomical correlates with
apathy (see 13 for a review). Although no single task captures all
domains and processes associated with executive function, there are
commonly used tasks that encompass relevant cognitive processes to
provide sensitivemarkers for executive function. For example, theDigit
Symbol Substitution test of the Wechsler Adult Intelligence Scale–
Revised (WAIS-R) depends on a combination of the components of
executive function (working memory, attentional control, and rule
sets), in addition to non-executive visuospatial domains and process-
ing speed.22,23 TheDigit Symbol test correlateswith othermeasures of
executive function and is sensitive to the presence of cognitive changes
in patients with frontal lobe damage and dementia.20,24–28 We there-
fore use the Digit Symbol test performance as an index of executive
dysfunction in presymptomatic FTD.
The causal relationship between apathy and executive dysfunction
in FTD remains unclear: specifically, whether apathy predicts cognitive
decline, or vice versa. This is especially relevant to the emergence of
FTD symptoms in those at genetic risk. A third of patients with FTD
present an autosomal dominant family history,29 with mutations of
three main genes accounting for about a fifth of cases: microtubule-
associated protein tau (MAPT), progranulin (GRN), and chromosome
9 open reading frame 72 (C9orf72).29,30 We therefore examined lon-
gitudinal changes in apathy and their association with subclinical cog-
nitive decline in presymptomatic gene carriers, in the international
Genetic FTD Initiative (GENFI).20
We first tested the hypothesis that apathy increases over time in
presymptomatic carriers of FTDmutations, and ismore severe in those
closer to symptom onset. We used latent growth curve modeling of
longitudinal data to test the predictive value of apathy for subclinical
deterioration of cognitive performance in theDigit Symbol test in gene
carriers versus non-carriers. To understand the relationship between
apathy and FTD-related brain changes, we tested whether baseline
and longitudinal changes in apathy were a function of atrophy in the
presymptomatic gene carriers. Previous studies suggest a detrimental
effect of apathy on clinical progression and survival of FTDpatients,5–9
Highlights
∙ Apathy progresses in presymptomatic genetic frontotem-
poral dementia
∙ Apathy predicts prospective cognitive decline, and not
vice versa
∙ Structural changes in frontal and cingulate regions predict
apathy progression
∙ Apathy is an early marker in frontotemporal dementia,
even before dementia onset
and have highlighted frontal lobe and cingulate cortex atrophy as neu-
ral correlates of apathy in FTD.13,14 Based on this, we predicted: (1)
that baseline apathy predicts future cognitive deterioration; and (2) an
association between apathy and structural brain change, in the frontal
lobe and cingulate cortex.
2 METHODS
2.1 Participants
From the GENFI study,20 DataFreeze 4 (2019), 600 participants were
included in this study: 304 presymptomatic mutation carriers (54 with
mutation in MAPT, 142 in GRN, and 108 in C9orf72), and 296 family
members without mutations (non-carrier control group). To meet the
inclusion criteria, all participants needed to not present another signif-
icantmedical or psychiatric condition thatwould interfere in their com-
pletion of assessments or impair their safety in the study. Participants
in pregnancy, or with contraindications toMRI were not recruited.
Participants underwent the GENFI standardized assessment. Dur-
ing the first visit, demographic informationof all participants, and infor-
mation regarding clinical background (neuropsychiatric features, fam-
ily and medical history, medication and symptoms) was collected. The
years to the expected symptom onset (EYO) variable for each subject
was defined by the mean within each family of affected relatives,20
while acknowledging that this is a weak predictor in GRN and C9orf72
families.31 Participants underwent a clinical and cognitive assessment
to evaluate their symptomatic status and the cognitive performance
at the baseline and annually for 2 years. This included structured
clinical examination and ratings of behavioral and neuropsychiatric
symptoms by clinicians (including sub-sections of the frontotemporal
lobar degeneration clinical dementia rating scale). Behavioral symp-
toms were assessed using the revised Cambridge Behavioural Inven-
tory (CBI-R). The neuropsychological battery included tests for lan-
guage, memory, and executive function. Non-language based tests rel-
evant to executive function included Digit Span Backwards from the
Wechsler Memory Scale-Revised, Trail Making Test B (TMT B), and
the WAIS-R Digit Symbol Substitution test.20 As the measure of apa-
thy severity, we used the motivation subscale of the CBI-R, which has
972 MALPETTI ET AL.
Research in context
1. Systematic review: Previous literature supports the role
of apathy in frontotemporal dementia as a disabling fea-
ture and risk factor for worse prognosis in terms of sur-
vival. However, its role as an early marker and predictor
of disease progression remains unclear.
2. Interpretation: In presymptomatic carriers of MAPT,
GRN, or C9orf72 mutations, apathy occurs early, wors-
ens over time, and predicts a subsequent subclinical dete-
rioration of cognitive performance. The progression of
apathy is also associated with early brain changes in the
frontal lobe and cingulate gyrus. Apathy represents an
early marker of cognitive decline and brain changes in
presymptomatic frontotemporal dementia.
3. Future directions: Apathy assessments in early stages of
frontotemporal dementia may improve cohorts’ stratifi-
cation and future therapeutic trials. Apathy may also be
a modifiable factor in its own right, and a target not only
for symptomatic treatment but also interventions to slow
down or delay clinical decline in people at risk of fron-
totemporal dementia.
been used to quantify apathy in previous studies of FTD.3,7 This sub-
scale assesses patients’ apathy through their carers’ responses on loss
of enthusiasm in personal interests, reduced interest in new things or
maintaining social relationships, and indifference to family members.
With our main focus on apathy, we excluded subjects without CBI-R
scores across visits (N = 53) from the initial DataFreeze 4 (N = 653).
To index executive cognitive deterioration, we used the WAIS-R Digit
Symbol test. This test has high test-retest reliability,32 making it suit-
able for longitudinal studies. In addition, presymptomatic carriers show
reduced performance almost 10 years before their expected age of
onset.20 We tested the correlation between Digit Symbol scores and
two other commonly used executive function related tests, the Digit
Span Backwards and TMT B. For each test and analysis, we included
z-scores based on gene-negative control group data at baseline. The
use of z-scores minimizes the risk of disclosure of genetic status and
meets our aim of quantifying the relative severity of symptoms within
the cohort, and their covariance with other cognitive and brain mea-
sures.
2.2 Imaging data acquisition and preprocessing
In DataFreeze 4, 573 out of 600 participants included in this
study had at least one volumetric T1-weighted MRI scan on 3T (or
1.5T scanners at sites where 3T scanning was not available) within
2 years of follow-up. Magnetization Prepared Rapid Gradient Echo
(MPRAGE) images were acquired at each site accommodating differ-
ent manufacturers and field strengths.20 Gray matter regional vol-
umes were extracted from the subcortical segmentation and cortical
parcellation labeled by the Desikan-Killiany Atlas in Freesurfer 6.0
(surfer.nmr.mgh.harvard.edu/). For cases with more than one scan, all
available follow-up images were included in the processing with the
longitudinal stream in Freesurfer, creating an unbiased within-subject
template for case-specific segmentation.33 Regional volumes were
combined into bilateral frontal, temporal (including amygdala and hip-
pocampus), parietal and occipital lobes, insula cortex, cingulate cortex,
subcortical central structures (basal ganglia and thalamus), and brain-
stem. Carriers’ volumes were z-scored with reference to non-carriers.
Total intracranial volume (TIV)wasestimatedas the sumof graymatter,
white matter, and cerebrospinal fluid segmentations using the Compu-
tational AnatomyToolbox (CAT12; http://www.neuro.uni-jena.de/cat/)
within Statistical Parametric Mapping software (SPM12; http://www.
fil.ion.ucl.ac.uk/spm/).CAT12alsoprovides imagingquality ratings con-
sidering noise,motion, and spatial resolution. Rawand parcellated data
were visually inspected, and imageswith significant artifacts, or parcel-
lation failure were excluded, such that all scans included in the analy-
ses hadCAT12 imaging quality ratings higher than 74/100 (mean: 84.2,
standard deviation: 1.3, range: 74 to 87).
2.3 Statistical analyses
2.3.1 Descriptive statistics
Baseline age, education, EYO, CBI-R apathy scores, and Digit Sym-
bol scores were compared between groups with a two independent-
samples t test. Sex was compared between groups with the chi-square
test. Within the two groups, for participants who presented scores> 0
at a depression severity clinical evaluation (0-3; N = 38 non-carriers,
N = 43 presymptomatic carriers), we tested the baseline associa-
tion between depression and apathy with the Independent Samples
Kruskal-Wallis Test.
2.3.2 Latent growth curve model
Univariate latent growth curve models (LGCMs) were fitted to
the combined data from three time points of longitudinal behav-
ioral/cognitive and imaging assessments, to test the relationships
between apathy, cognition, and brain volumes. The LGCM provides
insight into baseline scores, change, and individual differences by esti-
mating (1) an intercept, which represents the initial level of the out-
come measures; (2) a slope, quantifying the rate of change; (3) a vari-
ance of the intercept and slope, capturing individual differences in
baseline and change over time; and (4) the relation between intercept
and slope, that is, how the initial level is associated with the rate of
change over time. Predictors can be added to themodel to assess their
effects (as an interaction) with intercept and/or slope. The LGCM esti-
mation has twomain steps: (1) a linear or curvilinear regression is con-
ducted to fit across the repeated measures of each subject, eliciting a
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growth curve shape which describes the change over time; and (2) the
potential predictors of individual differences in intercepts/slopes are
then evaluated. In this way the growth model, as a collection of indi-
vidual trajectories, describes the individual differences in the changes
over time, and the changeat group level.34 LGCMis apowerful and flex-
ible tool well suited to specifying and testing hypotheses of changes,
predictors of change and clinical progression,34,35 and can be esti-
mated using open source software such as R (R Core Team). Compared
to simpler longitudinal analysis methods, LGCM is preferred for com-
plex models with more than one dependent variable and/or more than
one predictor, with complex variance functions, or multigroup model
estimation with partial constraints, to assess global model fit, and to
deal with random missing data.35 LGCM guidelines recommend ≥3
time points and ≥5 cases per parameter.35 These requirements were
met by our data. Our LGCM were estimated in the lavaan package36
using full informationmaximum likelihoodwith robust standard errors
todealwithmissingness andnon-normality. For eachmodel,we consid-
ered three main model fit indices37: (1) the root-mean-square error of
approximation (RMSEA, acceptable fit: <0.08, good fit: <0.05), (2) the
comparative fit index (CFI, acceptable fit: 0.95-0.97, good fit: >0.97),
and (3) the standardized root mean-square residual (SRMR, accept-
able fit: 0.05-0.10, good fit: <0.05). We also report the model chi-
square test (χ2), noting this index is sensitive to the sample size and
is liable to reject models of large cohorts (good fit: low values and
P > 0.05).37 We also report the ratio between chi-square and degrees
of freedom (χ2/df) as an alternative model fit index (acceptable fit: <2,
good fit: <3).37 To test group differences on parameters of interest in
LGCMs,we compared eachmodel to amodel that constrained the rele-
vantparameters (eg, the slope) tobeequal between the twogroups. For
model comparisons, we used Akaike Information Criteria (AIC), penal-
izingmodel complexity.
2.3.3 LGCM of apathy and cognitive decline
In all models, the intercept was centered at baseline and a linear slope
was tested. CBI-R apathy scores and Digit Symbol scores at follow-up
visits were annualized and recomputed at one and 2 years to adjust
for small differences in intervals. EYO was included as a predictor of
both intercept and slope, and the genetic status used to define groups.
We applied four different LGCMs to behavioral and cognitive data to
test our main hypothesis: (1) a LGCM on the longitudinal CBI-R apathy
subscale scores; (2) the same as the previous item, but with baseline
Digit Symbol as predictor; (3) a LGCMon the longitudinal Digit Symbol
scores; and (4) the same as the previous item, but with baseline CBI-R
apathy subscale scores as predictor. These four models allowed us to
test whether apathy progresses over time in presymptomatic carriers,
and predicts a subclinical cognitive deterioration, or vice versa.
First, an LGCMwas fitted on the CBI-R apathy z-scores, estimating
the parameters freely in a multigroup model defined by genetic diag-
nosis. This model was compared to one that was fitted by constraining
the slope estimation to be equal in the two groups, in order to test the
difference in fit of the group equality constrained model with the one
accounting for differences between presymptomatic carriers and non-
carriers on the annual rate of change (slope). Second, baseline Digit
Symbol scores were added to the model as predictor of both intercept
and slope of apathy, to test the predictive value of baseline cognitive
performance on longitudinal change in apathy. An analogous approach
was applied to the longitudinal and annualized Digit Symbol z-scores:
first, the initial LGCMwith EYO as predictor of the intercept and slope
was fitted in a multigroup model by freely estimating all parameters;
second, we compared this freemodel with amodel wherewe constrain
key parameters to test for between-group differences; and lastly, base-
line CBI-R apathy scores were added to the model as a predictor vari-
able on intercept and slope.
2.3.4 LGCM for structural brain changes
We applied eight independent univariate LGCMs to estimate longi-
tudinal changes in gray matter volumes of frontal, temporal, parietal
and occipital lobes, insular cortex, cingulate cortex, subcortical central
structures, and brainstem. As for the behavioral and cognitive scores,
all gray matter values at follow-up visits were computed at 1 and 2
years to adjust for small differences in retest interval. In all models,
the intercept was centered at baseline and a linear slope was tested.
EYO and TIV were included as predictors of both intercept and slope.
Genetic status (presymptomatic carrier versusnon-carrier) defined the
groups. When change is homogeneous, or modeled in smaller sub-
groups, LGCM estimation may occasionally yield improper solutions
(ie, impossible values such as negative variances) which necessitate
imposing constraints to achieve plausible solutions, whichwill be noted
when necessary. In presymptomatic carriers, we applied a bivariate
LGCMmodel on longitudinal apathy scores and longitudinal gray mat-
ter volumes in each of the brain regions that changed over time. With
thebivariate LGCMit is possible to investigate theassociationbetween
the annual rates of change (slopes) in the two variables considered, as
well as the associations between initial scores (intercepts) and the lon-
gitudinal changes. Thus, we tested our hypothesis on the association
between atrophy in fronto-cingulate brain regions and apathy sever-
ity in presymptomatic FTD. For these longitudinal analyses of imaging
data, we used an ROI-based approach that included the regional vol-
umes in the bivariate LGCMwith apathy.We considered bilateral lobar
values rather than single subregions or lateralized lobar values, to sim-
plify analyses and constrain the parameter-to-subject ratio. Although
individuals may have asymmetric atrophy, the group pattern is typi-
cally bilateral and symmetric. To assess the degree of symmetry, we
tested for brain volumedifferencesbetween left and right hemispheres
at baseline using a laterality index (absolute difference between left
and right volumes divided by total volume). We then applied t tests
on this index between presymptomatic carriers and non-carries, across
the whole population and by genetic mutation.
The parameters in each of these models are estimated indepen-
dently from the other region-specific models. We correct for multiple
comparisons for slope estimates and group comparisons across region-
specific tests, although itwould not be appropriate to apply corrections
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TABLE 1 Demographic and clinical characteristics at baseline for presymptomatic gene carriers and non-carrier subjects
Presymptomatic carriers Non-carriers P -value
N 304 296
Age (years; mean± SD) 44.5± 12.1 46.6± 14.0 0.044
Sex (Female/Male) 187/117 174/122 0.495
Education (years; mean± SD) 14.3± 3.4 13.9± 3.6 0.108
Estimated Years from symptomsOnset (years; mean± SD) –14.0± 12.1 –13.0± 14.1 0.347
CBI-R Apathy Baseline (z-scores; mean± SD) 0.3± 1.5 0.0± 1.0 0.015
Digit Symbol Baseline (z-scores; mean± SD) 0.1± 0.9 0.1± 1.0 0.948
Total Intracranial Volume Baseline (mean± SD) 1492.8± 142.8 1497.7± 141.2 0.684
Uncorrected P-values are the result of t test or χ2 tests as appropriate: none survive correction for multiple comparisons.
Abbreviation: CBI, Cambridge Behavioural Inventory.
to model fit indices across different models (ie, applying a correction
to the chi-square test of perfect fit would paradoxically improve the
apparent fit).We report uncorrected and correctedP-valueswith False




Demographic and clinical characteristics at baseline, and descriptive
statistics are summarized in Table 1. Presymptomatic carriers had
higher baseline apathy scores (P= 0.015), andwere on average 2 years
younger (P = 0.044) than non-carriers. At baseline, depression sever-
ity and CBI-R apathy scores were not significantly associated in either
non-carriers (N = 38, range depression scores: 0.5-3, mean = 1.01,
SD = 0.64; Test(3) = 4.134, P = 0.247) or presymptomatic carriers
(N = 43, range depression scores: 0.5-2, mean = 1.02, SD = 0.56;
Test(2)= 1.129, P= 0.569). Depression severity at baseline did not dif-
fer between the two groups (χ2(3)= 1.79, P= 0.618). At baseline, Digit
Symbol scores correlated with both TMT B (R = –0.581, P < 0.001)
and Digit Span Backwards (R = 0.368, P < 0.001). In addition, Digit
Symbol scores were positively associated with gray matter volumes
in frontal lobe (std beta = 0.337, P < 0.001, FDR P < 0.001), tempo-
ral lobe (std beta = 0.231, P = 0.0049, FDR P = 0.0071), parietal lobe
(std beta = 0.280, P < 0.001, FDR P = 0.00116), occipital lobe (std
beta= 0.210, P= 0.0016, FDR P= 0.0042), cingulate (std beta= 0.205,
P= 0.0053, FDR P= 0.0071), and central structures (std beta= 0.223,
P = 0.0051, FDR P = 0.0071), including TIV and EYO as covariates.
However, there was no significant effect of genetic status on this asso-
ciation (presymptomatic carriers vs. non-carriers; P> 0.05).
3.2 LGCM on longitudinal apathy scores
The LGCM on longitudinal CBI-R apathy scores fit the data well
(χ2[11]=11.59, P=0.395, χ2/df=1.05, RMSEA=0.025 [0.000-0.119],
CFI = 0.99, SRMR = 0.082), after imposing a necessary constraint
(slope variance and intercept-slope covariance to zero) in non-carriers.
Therewas a significant increase in apathy scores over time in presymp-
tomatic carriers (estimate [est] = 0.511, standard error (SE) = 0.177,
z-value = 2.879, p = 0.004), but not in non-carriers (est = 0.084,
SE = 0.081, z-value = 1.036, P = 0.300; Figure 1). Comparing the free
versus constrainedmodels, the groups differed significantly in the rate
of change of apathy (∆χ2 = 10.14, ∆df= 1, P= 0.0015). EYOwas asso-
ciated with initial values (intercept) of apathy in presymptomatic car-
riers (est = 0.154, SE = 0.70, z-value = 2.192, P = 0.028) and non-
carriers (est=0.109, SE=0.044, z-value=2.468,P=0.014) (Appendix,
Figure A1, Panel A, left graph), reflecting its association with age in
both groups. The effect of EYO on apathy slope in presymptomatic
carriers was not significant (est = 0.170, SE = 0.092, z-value = 1.834,
P = 0.067; Appendix, Figure A1, Panel A, right graph). Including base-
line Digit Symbol scores as a predictor, the model fit the data well
(χ2[13]=15.02,P=0.306, χ2/df=1.56, RMSEA=0.040 [0.000-0.113],
CFI=0.98, SRMR=0.073). In presymptomatic carriers, baseline cogni-
tive performance did not influence the rate of change in apathy (est= –
0.133, SE= 0.134, z-value= –0.988, std est= –0.140, P= 0.323).
In summary, presymptomatic carriers showed a longitudinal
increase in apathy severity over a 2-year period, which was greater
than non-carriers. This change was not predicted by Digit Symbol test
performance at baseline.
3.3 LGCM on longitudinal cognition
The LGCM on longitudinal Digit Symbol scores fit the data adequately
(χ2[11]=24.68,P=0.010, χ2/df=2.24, RMSEA=0.079 [0.037-0.121],
CFI = 0.97, SRMR = 0.034), after constraining slope variance and
intercept-slope covariance to zero in non-carriers. The rate of decline
was significant in presymptomatic carriers (est = –0.077, SE = 0.031,
z-value = –2.487, P = 0.013), but not in non-carriers (est = 0.002,
SE = 0.023, z-value = 0.107, P = 0.915). Comparing the models con-
firmed that groups differed significantly in the rate of cognitive decline
(∆χ2 = 3.912, ∆df = 1, P = 0.04796). EYO was associated with ini-
tial values (intercept) of Digit Symbol performance in presymptomatic
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F IGURE 1 Longitudinal increase in apathy scores over 2-year period in presymptomatic carriers (red) and non-carriers (blue). On the left, the
latent growth curvemodel applied to test longitudinal changes in apathy levels, as assessed by the apathy subscale of the revised Cambridge
Behavioural Inventory (CBI) over 2 years of follow-up, including the estimated years from onset (EYO) as covariate. Estimated regression values in
presymptomatic group are reported in italics (est= estimate; SE= standard error; z= z-value). The graph on the right represents apathy scores
(y-axis) at group level over 2-year follow-up visits (x-axis). Individuals’ data are not plotted, to protect anonymity. Abbreviation: Interc,
intercept.
carriers (est = –0.303, SE = 0.038, z-value = –7.885, P < 0.001) and
non-carriers (est = –0.279, SE = 0.039, z-value = –7.150, P < 0.001;
Appendix, Figure A1, Panel B, left graph). EYO also modulated the rate
of decline in presymptomatic carriers (est = –0.098, SE = 0.024, z-
value= –4.152, P< 0.001).
Including baseline CBI-R apathy scores as a predictor in the model
on Digit Symbol longitudinal scores, the model fit the data well
(χ2[13]=29.29, P=0.006, χ2/df=2.25, RMSEA=0.076 [0.039-0.113],
CFI = 0.97, SRMR = 0.030). The model identified a significant decline
in presymptomatic carriers only (est= –0.064, SE= 0.031, z-value= –
2.095, P= 0.036), with a significant effect of the baseline apathy sever-
ity on the rateof cognitivedecline (est=–0.038, SE=0.014, z-value=–
2.652, std est = –0.395, P = 0.008; Figure 2), but not on the inter-
cept (est = –0.053, SE = 0.033, z-value = –1.594, std est = –0.102,
P= 0.111).
In summary, presymptomatic carriers showed a progressive cogni-
tivedeclineover2years,whichwasgreater thannon-carriers. This sub-
clinical cognitive deterioration was faster when approaching the esti-
mated age of onset, and was predicted by apathy severity at the base-
line.
3.4 LGCM on longitudinal gray matter brain
volumes
Model fit indices for LGCM on z-scored brain volumes in cortical and
subcortical regions, and the estimated slope for both presymptomatic
carrier and non-carrier groups, are reported in Table 2. In summary,
for non-carriers there were no significant structural changes in the
regions of interest. In contrast, presymptomatic carriers showed pro-
gressive atrophy,whichwas significantly different from thenon-carrier
group, in the frontal, temporal, and parietal lobes, cingulate cortex
and in subcortical central structures (but not in the occipital lobe and
brainstem). Insular cortex showed longitudinal decline in the presymp-
tomatic group, but this did not significantly differ from non-carriers’
rate of change. In the model on parietal lobe values, the slope variance
term was constrained to zero in non-carriers to make the model con-
verge correctly. InAppendixB (TableB.1),wealso report anexploratory
analysis including the gene mutations as a grouping variable in the
univariate LGCMs, to estimate longitudinal changes by gene. Group
comparisons on annual rates of brain changes indicated differences
between gene mutation groups in the temporal lobe and insula. For
insula volume, the resultwasdrivenby theC9orf72group, showinggray
matter reduction over time. For temporal lobe volume both C9orf72
and MAPT groups showed a significant annual rate of atrophy, but
the GRN group did not. However, interpretation of this result requires
caution given the unbalanced sample size of the three gene mutation
groups.
The group comparisons on the laterality index for each lobar value
did not identify asymmetry between left and right volumes in presymp-
tomatic carriers as compared to non-carrier familymembers (P>0.05).
Considering the gene-specific groups, only insula showed an effect of
laterality (left > right volume, t = 2.00; P = 0.048) inMAPT carriers as
compared to the family non-carrier members.
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F IGURE 2 Effect of baseline apathy on the annual rate of change in Digit Symbol performance (’slope’). On the left, the latent growth curve
model applied to test the predictive value of baseline apathy levels, as assessed by the apathy subscale of the revised Cambridge Behavioural
Inventory (CBI), for longitudinal decline in Digit Symbol test performance over 2 years of follow-up. The estimated years from onset (EYO) was
included as covariate in themodel. Estimated regression values in presymptomatic group are reported in italics (est= estimate; SE= standard
error; z= z-value). The graph on the right represents the relationship between the estimated annual rate of change in Digit Symbol performance
(y-axis) and the baseline apathy scores (x-axis). Individuals’ data are not plotted, to protect anonymity. Abbreviations: Digit Symb, Digit Symbol
test; Interc, intercept.
3.5 Bivariate LGCMs on longitudinal apathy
scores and gray matter brain volumes
In the previous models of brain changes, significant longitudinal
changes in apathy and atrophy were identified in the presymptomatic
grouponly.We therefore applied five new, bivariate, LGCMsof longitu-
dinal apathy and apathy of frontal, temporal, and parietal lobes, cingu-
late cortex and the subcortical structures, constraining the covariance
termbetweenapathy intercept and slope to zero in allmodels toensure
proper solutions. We report model fit indices and estimated covari-
ance parameters for all brain regions in Table 3. In summary, the annual
progression of apathy severity was associated with baseline gray mat-
ter volumes in frontal lobe (est = –0.208, SE = 0.100, z = –2.077, std
est= –0.348,P=0.038) and cingulate cortex (est= –0.139, SE=0.058,
z=–2.085, std est=–0.237,P=0.037; Figure3). Comparing thebivari-
ate LGCMs with and without constraining the estimation of covari-
ance between brain volume intercept and progressive apathy to zero,
freely estimating the association between brain structure and apathy
change improved model fit for both frontal lobe (∆χ2 = 5.056, ∆df= 1,
P = 0.025) and cingulate cortex (∆χ2 = 7.206, ∆df = 1, P = 0.007)
gray matter volumes. With reduced sample sizes in gene specific sub-
groups, the LGCM method is not suitable for gene-specific analysis
in this dataset. Larger future datasets in GENFI, or merged datasets
between genetic FTD cohort studies, may enable gene-specific
modeling.
4 DISCUSSION
In this studywe found that apathy progresses significantly in presymp-
tomatic carriers of mutations associated with FTD, and that individ-
ual differences in apathy at baseline predict the severity of progres-
sive deterioration of performance on the Digit Symbol test over time.
In presymptomatic carriers, the progression of apathy over 2 years is
associatedwith atrophy of the frontal lobe and cingulate gyrus at base-
line. In contrast, subclinical cognitive impairments do not predict the
worsening of apathy.
Apathy is one of the most prevalent symptoms in patients with FTD
syndromes,38 and is associated with negative outcomes, such as cog-
nitive and functional decline, decreased quality of life, loss of inde-
pendence and poorer survival.4,5 Here we examined the relationship
between apathy and cognitive decline over time, through predictive
modeling of longitudinal change. Moreover, we did so in the context of
the long presymptomatic phase of FTD pathology, lasting many years
before dementia onset.19,20,39 Among ∼300 carriers, subclinical apa-
thy worsened over 2 years, and was more severe in older carriers.
This effect of time was observed with respect to the estimated year
of onset of dementia. In contrast, their relatives without mutations did
not show emergence of apathy. Carriers showed a similarly faster cog-
nitive deterioration, as assessed with Digit Symbol test performance,
before the critical functional threshold that underlines the diagno-
sis of dementia.19,20,39 The rate of cognitive decline was predicted by
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F IGURE 3 Bivariate latent growth curvemodel on apathy and graymatter volumes. On the left, the bivariate latent growth curvemodel
(LGCM) applied to test the relationship between longitudinal changes in apathy (’slope’), as assessed by the apathy-subscale of the revised
Cambridge Behavioural Inventory (CBI), and in graymatter (GM) volumes over 2 years of follow-up. The graphs on the right represent the
significant regressions identified by the bivariate LGCMs: annual rate of change in apathy scores (slope, y-axis) was associated with baseline gray
matter volumes in frontal lobe (x-axis, top graph) and cingulate cortex (x-axis, bottom graph). Estimated regression values in presymptomatic
group are reported in italics (est= estimate; SE= standard error; z= z-value). Individuals’ data are not plotted, to protect anonymity.
Abbreviations: EYO, estimated years from onset; Interc, intercept; TIV, total intracranial volume.
baseline apathy, but not vice versa, consistent with a predictive effect
of apathy on cognitive deterioration, over and above the presence of
apathy as an early manifestation of the genetic mutations.
Among the gene carriers, baseline gray matter volume of frontal
lobe and cingulate cortex predicted the faster progression of apathy
over 2 years. Apathy therefore represents an early neurobehavioral
marker that is related to the underlying FTD pathology. Rohrer et al.20
reported cross-sectional atrophy in presymptomatic and symptomatic
carriers ofmutations inMAPT,GRN, orC9orf72. In relation to estimated
year of onset of dementia, there was early volume loss of the insula
and temporal lobe (∼10 years before expected symptoms onset), fol-
lowed by the frontal lobe and subcortical structures (∼5 years before
expected onset), parietal and cingulate gyrus (around time of expected
onset), and occipital lobe (∼5 years after expected onset). How-
ever, cross-sectional studies are not always predictive of longitudinal
changes, and are not informative on causality or thedirection of causal-
ity. In this larger and longitudinal sample of presymptomatic carriers,
the cross-sectional and longitudinal data are concordant on the pro-
gression of apathy and atrophy, and their association in the frontal and
cingulate regions.3,10–12 We pooled our analyses over the pathogenic
mutations of MAPT, GRN and C9orf72. The sample size of the genetic
subgroups is not sufficient for valid LGCM modeling of separate gene
effects, and we cannot use this method with only 304 presymptomatic
carrier participants (54withMAPTmutations, 142withGRNmutations
and 108 with C9orf72 mutations) to compare gene effects. There is
some evidence of genetic moderation of apathy in dementia, such as
the apolipoprotein E gene (APOE) ε4 allele in Alzheimer’s disease,40 as
well as C9orf72 and GRN mutations in FTD.41 For example, up to 88%
of patients with C9orf72 expansions are reported to develop severe
apathy, often as a presenting symptom (see review42). Apathy has
been reported in ∼69% of patients with GRN mutations,43 but is less
common with MAPT mutations.41,44,45 Although apathy is sometimes
reported as more common than disinhibition,45 apathy and disinhi-
bition are strongly positively associated.10 Across all three genes, a
recent study reported apathy as the most frequent initial symptom in
patients with genetic FTD.46
There are several limitations to this study. Apathy is a multidimen-
sional construct that is often considered in terms of affective, cog-
nitive, and behavioral components, leading to reduced goal-directed
behaviors. These apathy domains have been identified in patients with



















































































































































































































































































































































































































































































































































































































































































































































































































































































































FTD, and are associated with lesions or dysfunction involving the
fronto-subcortical networks.13,47 We quantified apathy from the sub-
scale of CBI-R, as it was the principal measure for apathy available in
presymptomatic cases from the GENFI study. Although this has been
successfully employed in previous studies on FTD, and more recently
also in presymptomatic FTD,46 this questionnaire is not designed to
tease apart the subcomponents of apathy. In addition, as for other
carer ratings scales, the emotional distress, personal background, and
awareness about the illness may bias the carer’s evaluation. How-
ever, our results align with evidence in symptomatic FTD patients,
showing an early association of apathy reported by patients’ carers
with frontal and cingulate gray matter volume degeneration.13,14 Sim-
ilarly, in patients with syndromes of frontotemporal lobar degenera-
tion including FTD, Lansdall et al. reported a significant association of
carers’ ratings for apathy with diffuse atrophy in the fronto-striatum,
cingulate, and temporal regions.3 Overall these findings suggest a clin-
icopathological association between apathy severity, as reported by
carers, and neurodegeneration in key regions associated with moti-
vation. The GENFI study did not include self-rated scales for apathy,
which rely on insight and introspection abilities that may be lacking
in patients with FTD. However, future studies on the presymptomatic
phase of FTD may consider also investigating longitudinal changes
in self-rating apathy scores and multimodal apathy assessments (eg,
behavioral tests, computer tasks, patient and carer’s ratings and ques-
tionnaires) to estimate separate domains of the multidimensional con-
struct of apathy, and their associations with cognitive decline.
Executive dysfunction is common in all three genotypes.20,45 We
quantified cognitive decline with the WAIS-R Digit Symbol test, which
is sensitive to changes in executive function and frontal lobe damage.
This test has high test-retest reliability32 and is not a language-based
task, making it well suited to a longitudinal andmultinational study like
GENFI. The Digit Symbol test involves a range of cognitive operations,
not only executive functions but also visuoperceptual scanning and the
ability to write or draw.22 These are related to visuospatial and motor
systems that are not typically impaired in early stages of FTD. How-
ever, it does not in itself allow one to dissociate the potential elements
of executive cognition, such as selective working memory, inhibitory
controls or planning. Given the range of cognitive operations involved
in the performance of this test, it might reflect generalized cognitive
decline, rather than specific deficits related to executive dysfunction.
Nonetheless, in our cohort, Digit Symbol scores correlated strongly
with the performance on other executive function tests, and emerged
as themost sensitivemeasure in capturing a subclinical cognitive dete-
rioration in presymptomatic gene carriers.
Another challenge in the quantification of apathy and executive
function is the potential overlap with other symptoms, such as depres-
sion and akinesia.38 In particular, depression might be a confounding
symptom for apathy. The wider spectrum of neuropsychiatric symp-
toms has been described in GENFI, at least in terms of cross-sectional
prevalence of symptoms/signs and their neural correlates.46,48 Our
study and hypothesis focused on apathy, but we verified that depres-
sion and apathy measures were not significantly associated. This sug-
gests that the CBI-R apathy subscale is not simply measuring, or
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confounded by, depression symptoms. This aligns with previous evi-
dence that supports the dissociation between apathy and depression
in FTD and other neurodegenerative diseases.15,49–53 While akine-
sia is common in symptomatic genetic FTD,54 it is not common in
presymptomatic cases and does not correlate with apathy measures
in other cohorts.10 Finally, an open longitudinal study like GENFI will
have incomplete longitudinal data.We therefore included only the first
three waves of assessment, fulfilling the minimum requirement in the
LGCM guidelines.35 In years to come, it will be possible to examine
a larger data sample and/or a longer follow-up period, including the
role of apathy in the transition from presymptomatic to symptomatic
phases of FTD, and the relationship between apathy, cognitive, and
brain changes by genemutation groups.
To conclude, our results demonstrate that apathy occurs early in
disease progression of genetic FTD, reflecting early brain changes
and predicting individual future clinical trajectories of cognitive and
executive function deterioration. The assessment of apathy could help
with cohorts’ stratification, according to their prognosis, and improve
the power and design of future therapeutic trials. Apathy may also
be a modifiable factor in its own right, by pharmacological55 or non-
pharmacological interventions.56 As such, it becomes a potential tar-
get not only for symptomatic treatment but also interventions to slow
down or delay clinical decline in people at risk of FTD.
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APPENDIX A
F IGURE A1 Cross-sectional and longitudinal changes in apathy severity as assessed by the Cambridge Behavioural Inventory (CBI-apathy)
and Digit Symbol performance in presymptomatic carriers (red) and non-carriers (blue). (A) Graphs represent the relationships of the estimated
initial scores (“intercept”; left graph) and the annual rate of change (“slope”; right graph) in apathy scores with the estimated years from onset
(EYO). (B) Graphs represent the relationships of the estimated intercept (left graph) and slope (right graph) in Digit Symbol test scores with EYO.
Individuals’ data are not plotted, to protect anonymity.
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